Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period
Top Cited Papers
Open Access
- 4 June 2019
- journal article
- research article
- Published by Springer Nature in Calcified Tissue International
- Vol. 105 (3) , 271-284
Abstract
Burosumab, a fully human monoclonal antibody to FGF23, is the only approved treatment for X-linked hypophosphatemia (XLH), a rare genetic disorder characterized by renal phosphate wasting and substantial cumulative musculoskeletal morbidity. During an initial 24-week randomized, controlled trial, 134 adults with XLH received burosumab 1 mg/kg (n = 68) or placebo (n = 66) every 4 weeks. After 24 weeks, all subjects received open-label burosumab until week 48. This report describes the efficacy and safety of burosumab during the open-label treatment period. From weeks 24–48, serum phosphorus concentrations remained normal in 83.8% of participants who received burosumab throughout and were normalized in 89.4% who received burosumab after placebo. By week 48, 63.1% of baseline fractures/pseudofractures healed fully with burosumab, compared with 35.2% with burosumab after placebo. In both groups, burosumab was associated with clinically significant and sustained improvement from baseline to week 48 in scores for patient-reported outcomes of stiffness, pain, physical function, and total distance walked in 6 min. Rates of adverse events were similar for burosumab and placebo. There were no fatal adverse events or treatment-related serious adverse events. Nephrocalcinosis scores did not change from baseline by more than one grade at either week 24 or 48. These data demonstrate that in participants with XLH, continued treatment with burosumab is well tolerated and leads to sustained correction of serum phosphorus levels, continued healing of fractures and pseudofractures, and sustained improvement in key musculoskeletal impairments.Keywords
Funding Information
- Ultragenyx Pharmaceutical
This publication has 18 references indexed in Scilit:
- Outcome of adult patients with X‐linked hypophosphatemia caused by PHEX gene mutationsJournal of Inherited Metabolic Disease, 2018
- Therapeutic management of hypophosphatemic rickets from infancy to adulthoodEndocrine Connections, 2014
- Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemiaJournal of Clinical Investigation, 2014
- FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate HomeostasisJournal of Bone and Mineral Research, 2004
- Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked HypophosphatemiaNew England Journal of Medicine, 2003
- A gene (PEX) with homologies to endopeptidases is mutated in patients with X–linked hypophosphatemic ricketsNature Genetics, 1995
- Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus diseasePediatric Nephrology, 1995
- Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets.The Journal of Clinical Endocrinology & Metabolism, 1992
- Effects of Therapy in X-Linked Hypophosphatemic RicketsNew England Journal of Medicine, 1991
- X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features.Radiology, 1989